Aldeyra Therapeutics, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 3 | -$0.11 | -$0.11 | -$0.11 |
| Q2 2024 | 2 | -$0.21 | -$0.21 | -$0.21 |
| Q3 2024 | 1 | -$0.24 | -$0.24 | -$0.24 |
| Q4 2024 | 4 | -$0.26 | -$0.17 | -$0.23 |
| Q1 2025 | 1 | -$0.22 | -$0.22 | -$0.22 |
| Q2 2025 | 1 | -$0.22 | -$0.22 | -$0.22 |
| Q3 2025 | 1 | -$0.25 | -$0.25 | -$0.25 |
| Q4 2025 | 1 | -$0.25 | -$0.25 | -$0.25 |
Aldeyra Therapeutics, Inc. Earnings Date And Information
Aldeyra Therapeutics, Inc. last posted its earnings results on Thursday, November 7th, 2024. The company reported $-0.25 earnings per share for the quarter, missing analysts' consensus estimates of $-0.25 by $0. The company had revenue of 0 for the quarter and had revenue of 0 for the year. Aldeyra Therapeutics, Inc. has generated $-1 earnings per share over the last year ($-0.64 diluted earnings per share) and currently has a price-to-earnings ratio of -6.45. Aldeyra Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 6th, 2025 based on prior year's report dates.
Aldeyra Therapeutics, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/07/2024 | Q3 2024 | -$0.25 | -$0.25 | 0 | $0 | $0 |
| 08/01/2024 | Q2 2024 | -$0.28 | $0 | $0 | ||
| 05/02/2024 | Q1 2024 | -$0.08 | -$0.14 | -0.06 | $0 | |
| 03/07/2024 | Q4 2023 | -$0.21 | -$0.08 | 0.13 | $392,620 | |
| 11/03/2023 | Q3 2023 | -$0.24 | -$0.14 | 0.1 | $0 | |
| 08/03/2023 | Q2 2023 | -$0.31 | -$0.15 | 0.16 | $0 | |
| 05/04/2023 | Q1 2023 | -$0.30 | -$0.25 | 0.05 | $0 | |
| 04/28/2023 | Q4 2022 | -$0.21 | $0 | |||
| 11/10/2022 | Q3 2022 | -$0.34 | -$0.24 | 0.1 | $0 | |
| 08/05/2022 | Q2 2022 | -$0.32 | -$0.31 | 0.01 | $0 | |
| 05/05/2022 | Q1 2022 | -$0.31 | -$0.29 | 0.02 | $0 | |
| 03/17/2022 | Q4 2021 | -$0.31 | -$0.27 | 0.04 | $0 | |
| 10/28/2021 | Q3 2021 | -$0.29 | -$0.27 | 0.02 | $-46 | $0 |
| 08/05/2021 | Q2 2021 | -$0.27 | -$0.28 | -0.01 | $0 | |
| 05/06/2021 | Q1 2021 | -$0.29 | -$0.25 | 0.04 | $0 | |
| 03/11/2021 | Q4 2020 | -$0.26 | -$0.25 | 0.01 | $0 | |
| 11/05/2020 | Q3 2020 | -$0.28 | -$0.23 | 0.05 | $0 | |
| 08/06/2020 | Q2 2020 | -$0.34 | -$0.25 | 0.09 | $0 | |
| 05/07/2020 | Q1 2020 | -$0.48 | -$0.34 | 0.14 | $0 | |
| 03/12/2020 | Q4 2019 | -$0.68 | -$0.45 | 0.23 | $0 |
Aldeyra Therapeutics, Inc. Earnings: Frequently Asked Questions
-
When is Aldeyra Therapeutics, Inc.'s earnings date?
Aldeyra Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 6th, 2025 based off last year's report dates.
-
How can I listen to Aldeyra Therapeutics, Inc.'s earnings conference call?
The conference call for Aldeyra Therapeutics, Inc.'s latest earnings report can be listened to online.
-
How can I read Aldeyra Therapeutics, Inc.'s conference call transcript?
The conference call transcript for Aldeyra Therapeutics, Inc.'s latest earnings report can be read online.
-
How much profit does Aldeyra Therapeutics, Inc. generate each year?
Aldeyra Therapeutics, Inc. (:ALDX) has a recorded net income of $0. Aldeyra Therapeutics, Inc. has generated $-0.64 earnings per share over the last four quarters.
-
What is Aldeyra Therapeutics, Inc.'s price-to-earnings ratio?
Aldeyra Therapeutics, Inc. (:ALDX) has a price-to-earnings ratio of -6.45 and price/earnings-to-growth ratio is 0.37.
